Regulatory Novo Nordisk preps filings for sickle cell drug etavopivat PharmaphorumNovo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease.RegulatoryHematologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Novo Nordisk has claimed a key win in its head-to-head race with Agios to bring an oral PKR activator to the market for sickle cell disease. RegulatoryHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new dataNext: Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
